特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
939992

市場のスポットライト:ホジキンリンパ腫

Market Spotlight: Hodgkin's Lymphoma

出版日: | 発行: Datamonitor Healthcare | ページ情報: 英文 41 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.84円
市場のスポットライト:ホジキンリンパ腫
出版日: 2020年08月10日
発行: Datamonitor Healthcare
ページ情報: 英文 41 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

当レポートは、世界のホジキンリンパ腫関連市場を調査したもので、疾患の背景、治療法、疫学、上市されている医薬品、パイプライン上にある医薬品、薬事規制面の重要な動き、ライセンス供与と資産買収、親特許、収益機会、臨床試験の状況などの情報を提供するとともに、アナリストやオピニオンリーダーの見解も紹介しています。

目次

概要

主な調査結果

疾患の背景

  • 亜類型

治療法

  • 化学療法
  • 放射線治療
  • 免疫療法
  • 幹細胞移植(SCT)

疫学

上市されている医薬品

パイプライン上にある医薬品

最新動向とアナリストの意見

  • Keytruda(2020年3月2日)
  • Folotyn(2019年1月17日)

今後の主な動き

規制面の主な動き

  • 標準審査

成功の可能性

ライセンス供与と資産買収契約

  • BeiGene、Bristol/Celgene 合併前にTislelizumabを再取得

親特許

収益機会

臨床試験の情勢

  • 各段階の治験依頼者
  • 各相の治験依頼者

参考文献

  • 処方薬に関する情報

付録

目次
Product Code: DMKC0185142

This Market Spotlight report covers the Hodgkin's Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, key upcoming and regulatory events, recent events and analyst opinion, patent information, a 10-year disease incidence forecast, probability of success, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2019, there were 80,800 incident cases of Hodgkin's lymphoma worldwide, and expects that number to increase to 86,500 incident cases by 2028. * In the same year, there were approximately 277,600 five-year prevalent cases of Hodgkin's lymphoma worldwide, which is expected to increase to 295,000 five-year prevalent cases by 2028.

The approved drugs in the Hodgkin's lymphoma space target antibody-drug conjugate, cluster of differentiation 30/tumor necrosis factor receptor superfamily member 8, microtubules, DNA, the immune system, and programmed death-1 receptor/programmed death ligands. The majority of the approved drugs are administered via the intravenous route.

The majority of the industry-sponsored drugs in active clinical development for Hodgkin's lymphoma are in Phase II, with no drugs in Phase III.

Therapies in the pipeline for Hodgkin's lymphoma focus on a wide variety of targets. The majority of the pipeline drugs in development are administered via the intravenous route, with the remainder being tested in oral, intratumoral, and subcutaneous formulations.

The only high-impact upcoming event for drugs in the Hodgkin's lymphoma space is topline Phase II trial results for ADCT-301. The overall likelihood of approval of a Phase I hematologic asset is 9.9%, and the average probability a drug advances from Phase III is 61.4%. Drugs, on average, take 9.1 years from Phase I to approval, compared to 9.4 years in the overall oncology space.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for Hodgkin's lymphoma have been in the early and mid-phases of development, with 93% of trials in Phase I-II, and only 7% in Phase III-IV.

The US has a substantial lead in the number of Hodgkin's lymphoma clinical trials globally. France leads the major European markets, while China has the top spot in Asia.

Clinical trial activity in the Hodgkin's lymphoma space is dominated by completed trials. Takeda has the highest number of completed clinical trials for Hodgkin's lymphoma, with 50 trials.

Takeda leads industry sponsors with the highest overall number of clinical trials for Hodgkin's lymphoma, followed by Bristol Myers Squibb.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

  • Chemotherapy
  • Radiation therapy
  • Immunotherapy
  • Stem cell transplantation (SCT)

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Keytruda for Hodgkin's Lymphoma (May 13, 2020)
  • Keytruda for Hodgkin's Lymphoma (March 2, 2020)
  • Folotyn for Hodgkin's Lymphoma (January 17, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • New Approvals, Biosecurity In Spotlight As China Gears For National Congress
  • A Slew Of Standard Reviews

PROBABILITY OF SUCCESS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in incident cases of Hodgkin's lymphoma, 2019-28
  • Figure 2: Overview of pipeline drugs for Hodgkin's lymphoma in the US
  • Figure 3: Pipeline drugs for Hodgkin's lymphoma, by company
  • Figure 4: Pipeline drugs for Hodgkin's lymphoma, by drug type
  • Figure 5: Pipeline drugs for Hodgkin's lymphoma, by classification
  • Figure 6: Keytruda for Hodgkin's Lymphoma (May 13, 2020): Phase III - KEYNOTE-204
  • Figure 7: Keytruda for Hodgkin's Lymphoma (March 2, 2020): Phase III - KEYNOTE-204
  • Figure 8: Key upcoming events in Hodgkin's lymphoma
  • Figure 9: Probability of success in the Hodgkin's lymphoma pipeline
  • Figure 10: Clinical trials in Hodgkin's lymphoma
  • Figure 11: Top 10 drugs for clinical trials in Hodgkin's lymphoma
  • Figure 12: Top 10 companies for clinical trials in Hodgkin's lymphoma
  • Figure 13: Trial locations in Hodgkin's lymphoma
  • Figure 14: Hodgkin's lymphoma trials status
  • Figure 15: Hodgkin's lymphoma trials sponsors, by phase

LIST OF TABLES

  • Table 1: Incident cases of Hodgkin's lymphoma, 2019-28
  • Table 2: Five-year prevalent cases of Hodgkin's lymphoma, 2019-28
  • Table 3: Marketed drugs for Hodgkin's lymphoma
  • Table 4: Pipeline drugs for Hodgkin's lymphoma in the US
  • Table 5: Keytruda for Hodgkin's Lymphoma (May 13, 2020)
  • Table 6: Keytruda for Hodgkin's Lymphoma (March 2, 2020)
  • Table 7: Folotyn for Hodgkin's Lymphoma (January 17, 2019)
  • Table 8: Historical global sales, by drug ($m), 2015-19
  • Table 9: Forecasted global sales, by drug ($m), 2020-24
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.